$ARTH
Arch Therapeutics, Inc.

2015 Q1 Form 10-Q Financial Statement

#000114420415028272 Filed on May 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q3 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $850.0K $860.0K $810.0K
YoY Change 4.94% 575.0%
% of Gross Profit
Research & Development $402.5K $530.0K $487.1K
YoY Change -17.37% 5171.54%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.256M $1.390M $1.296M
YoY Change -3.08% 44.79% 921.03%
Operating Profit -$1.256M -$1.296M
YoY Change -3.08% 921.03%
Interest Expense $50.56K $2.020M $27.77K
YoY Change 82.09% -39.38%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$830.0K $640.0K -$8.380M
YoY Change -90.1% -166.67% 4829.41%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$834.0K $640.0K -$8.380M
YoY Change -90.05% -166.67% 4753.11%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.12
Diluted Earnings Per Share -$10.91K $8.868K -$124.4K
COMMON SHARES
Basic Shares Outstanding 76.08M shares 72.08M shares 67.34M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q3 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $570.0K $830.0K $2.630M
YoY Change -78.33% 48.21%
Cash & Equivalents $573.6K $833.5K $2.631M
Short-Term Investments
Other Short-Term Assets $30.00K $40.00K $30.00K
YoY Change 0.0% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $606.0K $877.0K $2.660M
YoY Change -77.22% -44.39%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $10.00K
YoY Change -100.0%
Total Long-Term Assets $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $606.0K $877.0K $2.660M
Total Long-Term Assets $0.00 $0.00 $10.00K
Total Assets $606.0K $877.0K $2.670M
YoY Change -77.3% -44.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $204.1K $175.8K $100.0K
YoY Change 104.1% -44.14%
Accrued Expenses $330.0K $270.0K $150.0K
YoY Change 120.0% 92.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $410.0K
YoY Change
Total Short-Term Liabilities $1.392M $2.724M $4.370M
YoY Change -68.14% 497.81% 43600.0%
LONG-TERM LIABILITIES
Long-Term Debt $960.0K $960.0K $950.0K
YoY Change 1.05% 2.13%
Other Long-Term Liabilities $4.180M $4.090M $5.840M
YoY Change -28.42%
Total Long-Term Liabilities $5.143M $5.046M $6.790M
YoY Change -24.25% 434.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.392M $2.724M $4.370M
Total Long-Term Liabilities $5.143M $5.046M $6.790M
Total Liabilities $6.535M $7.769M $11.16M
YoY Change -41.44% 454.83% 111500.0%
SHAREHOLDERS EQUITY
Retained Earnings -$13.23M -$12.77M
YoY Change 175.8%
Common Stock $7.300M $5.882M
YoY Change 9680.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.929M -$6.892M -$8.490M
YoY Change
Total Liabilities & Shareholders Equity $606.0K $877.0K $2.670M
YoY Change -77.3% -44.75%

Cashflow Statement

Concept 2015 Q1 2014 Q3 2014 Q1
OPERATING ACTIVITIES
Net Income -$834.0K $640.0K -$8.380M
YoY Change -90.05% -166.67% 4753.11%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$960.0K -$970.0K -$1.030M
YoY Change -6.8% 46.97% 635.71%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 750.0K 0.000 2.720M
YoY Change -72.43% -100.0% 2166.67%
NET CHANGE
Cash From Operating Activities -960.0K -970.0K -1.030M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 750.0K 0.000 2.720M
Net Change In Cash -210.0K -970.0K 1.690M
YoY Change -112.43% -1177.78% -8550.0%
FREE CASH FLOW
Cash From Operating Activities -$960.0K -$970.0K -$1.030M
Capital Expenditures $0.00
Free Cash Flow -$1.030M
YoY Change 635.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32441 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
43470 USD
CY2014Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
267835 USD
CY2015Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
448776 USD
CY2014Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2280000 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1392163 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2723667 USD
CY2015Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
961295 USD
CY2014Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
955766 USD
CY2015Q1 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
155000 USD
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
100000 USD
CY2015Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4026950 USD
CY2014Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3990000 USD
CY2015Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5143245 USD
CY2014Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5045766 USD
CY2015Q1 us-gaap Liabilities
Liabilities
6535408 USD
CY2014Q3 us-gaap Liabilities
Liabilities
7769433 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
573600 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
833520 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
606041 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
876990 USD
CY2015Q1 us-gaap Assets
Assets
606041 USD
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
204099 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
175832 USD
CY2015Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
329485 USD
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
76076 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
72051 USD
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7224072 USD
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5810200 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13229515 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12774694 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
-5929367 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-6892443 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
606041 USD
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76076487 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72076487 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76076487 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72076487 shares
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
876990 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0px; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Concentration of Credit Risk</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
1096278 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
484875 USD
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q1 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
10391693 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2850000 USD
CY2014Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
484875 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
3849448 USD
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4213595 USD
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
6270000 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8637962 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2987500 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
-7399875 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11625492 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.19
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.31
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
0.32
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.31
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M28D
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P4Y10M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y4M28D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7750 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
5243 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
7750 USD
CY2014Q1 us-gaap Revenues
Revenues
0 USD
CY2015Q1 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
808483 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
853177 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1445492 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1723533 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
487090 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
402495 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
630756 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
802230 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
1295573 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
1255672 USD
us-gaap Operating Expenses
OperatingExpenses
2076248 USD
us-gaap Operating Expenses
OperatingExpenses
2525763 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1295573 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1255672 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2076248 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2525763 USD
CY2014Q1 us-gaap Interest Expense
InterestExpense
27765 USD
CY2015Q1 us-gaap Interest Expense
InterestExpense
50556 USD
us-gaap Interest Expense
InterestExpense
55530 USD
us-gaap Interest Expense
InterestExpense
78320 USD
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-7084583 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-833966 USD
CY2015Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
421706 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-7112348 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2070942 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-8380156 USD
us-gaap Net Income Loss
NetIncomeLoss
-454821 USD
us-gaap Net Income Loss
NetIncomeLoss
-9188596 USD
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67344404 shares
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76076487 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63744820 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74716734 shares
CY2013Q2 arth Increase In Aggregate Number Of Shares
IncreaseInAggregateNumberOfShares
3000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.766 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.194 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0025 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0240 pure
CY2015Q1 arth Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
957544 shares
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
372000 USD
CY2014Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
5529 USD
CY2015Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
2764 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
5529 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
2764 USD
CY2015Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
961295 USD
CY2014Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
955766 USD
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
92500 USD
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
503355 USD
us-gaap Share Based Compensation
ShareBasedCompensation
609272 USD
arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
55530 USD
arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
78320 USD
arth Non Cash Expense For Issuance Of Warrants
NonCashExpenseForIssuanceOfWarrants
7541693 USD
arth Non Cash Expense For Issuance Of Warrants
NonCashExpenseForIssuanceOfWarrants
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
51750 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
8625 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11288 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11029 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
28267 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1641437 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1809920 USD
arth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
2715403 USD
arth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
750000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1000000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3715403 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1550000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2073966 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-259920 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
557319 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2631285 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
800000 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-484875 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-3849448 USD
CY2014Q1 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
0 USD
CY2015Q1 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
0 USD
arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
0 USD
arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
224000 USD
CY2014Q1 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
0 USD
CY2015Q1 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
624016 USD
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
0 USD
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
1924186 USD
arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
0 USD
arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
-1924186 USD
CY2015Q1 arth Gain On Warrant Derivative Modification
GainOnWarrantDerivativeModification
624016 USD
arth Gain On Warrant Derivative Modification
GainOnWarrantDerivativeModification
1924186 USD
CY2014Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
224000 USD
CY2015Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
409803 USD
CY2014Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2014Q1 arth Fair Value Of Derivative Liabilities In Excess Of Proceeds
FairValueOfDerivativeLiabilitiesInExcessOfProceeds
-7541693 USD
CY2015Q1 arth Fair Value Of Derivative Liabilities In Excess Of Proceeds
FairValueOfDerivativeLiabilitiesInExcessOfProceeds
0 USD
arth Fair Value Of Derivative Liabilities In Excess Of Proceeds
FairValueOfDerivativeLiabilitiesInExcessOfProceeds
-7541693 USD
arth Fair Value Of Derivative Liabilities In Excess Of Proceeds
FairValueOfDerivativeLiabilitiesInExcessOfProceeds
0 USD
CY2015Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.20

Files In Submission

Name View Source Status
0001144204-15-028272-index-headers.html Edgar Link pending
0001144204-15-028272-index.html Edgar Link pending
0001144204-15-028272.txt Edgar Link pending
0001144204-15-028272-xbrl.zip Edgar Link pending
arth-20150331.xml Edgar Link completed
arth-20150331.xsd Edgar Link pending
arth-20150331_cal.xml Edgar Link unprocessable
arth-20150331_def.xml Edgar Link unprocessable
arth-20150331_lab.xml Edgar Link unprocessable
arth-20150331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v409195_10q.htm Edgar Link pending
v409195_ex31-1.htm Edgar Link pending
v409195_ex31-2.htm Edgar Link pending
v409195_ex32-1.htm Edgar Link pending